Research programme: peptide therapeutics transdermal - Zealand Pharma
Latest Information Update: 14 Jul 2011
At a glance
- Originator Zealand Pharma
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 16 Apr 2009 Investigation in Undefined indication in Denmark (Transdermal)